Cardiovascular disease therapeutics via engineered oral microbiota: Applications and perspective

IF 23.7 Q1 MICROBIOLOGY

iMeta Pub Date : 2024-05-09 DOI:10.1002/imt2.197

Wenyu Zhen, Zifei Wang, Qing Wang, Wansu Sun, Rui Wang, Wenhao Zhang, Yulong Zhang, Wengang Qin, Bang Li, Qingqing Wang, Biao Hong, Yicheng Yang, Jing Xu, Siyu Ma, Ming Da, Linfei Feng, Xiaodong Zang, Xuming Mo, Xiaoyu Sun, Mingyue Wu, Junji Xu, Jianguang Xu, Yuan Huang, Hengguo Zhang

{"title":"Cardiovascular disease therapeutics via engineered oral microbiota: Applications and perspective","authors":"Wenyu Zhen, Zifei Wang, Qing Wang, Wansu Sun, Rui Wang, Wenhao Zhang, Yulong Zhang, Wengang Qin, Bang Li, Qingqing Wang, Biao Hong, Yicheng Yang, Jing Xu, Siyu Ma, Ming Da, Linfei Feng, Xiaodong Zang, Xuming Mo, Xiaoyu Sun, Mingyue Wu, Junji Xu, Jianguang Xu, Yuan Huang, Hengguo Zhang","doi":"10.1002/imt2.197","DOIUrl":null,"url":null,"abstract":"<p>Engineering bacteria are considered as a potential treatment for cardiovascular diseases and related risk factors. Oral bacteria are closely related to the occurrence and development of cardiovascular diseases, and their engineering has broad prospects and potential in the treatment of cardiovascular diseases. Oral pathogenic bacteria undergo protein and genetic engineering, including the incorporation of exogenous plasmids to yield therapeutic effects; genetically engineered oral probiotics can be harnessed to secrete cytokines and reactive oxygen species, offering novel therapeutic avenues for cardiovascular diseases.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":"3 3","pages":""},"PeriodicalIF":23.7000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.197","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Engineering bacteria are considered as a potential treatment for cardiovascular diseases and related risk factors. Oral bacteria are closely related to the occurrence and development of cardiovascular diseases, and their engineering has broad prospects and potential in the treatment of cardiovascular diseases. Oral pathogenic bacteria undergo protein and genetic engineering, including the incorporation of exogenous plasmids to yield therapeutic effects; genetically engineered oral probiotics can be harnessed to secrete cytokines and reactive oxygen species, offering novel therapeutic avenues for cardiovascular diseases.

Abstract Image